Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.44 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297408 | 1.00 | KIF11 (0.53) | KIF11DAOKDM1ALOXL2LOX | |
| SCHEMBL4391582 | 0.86 | TAAR1 (0.53) | KIF11DAOKDM1ATAAR1MAOB | |
| Hydrochloric Acid SCHEMBL3570176 | 0.84 | TAAR1 (0.52) | KIF11DAOKDM1ATAAR1MAOB | |
| SCHEMBL18266700 | 0.84 | LOXL2 (0.40) | KIF11DAOKDM1ALOXL2LOX | |
| SCHEMBL41769 | 0.83 | PTPN7 (0.45) | KIF11LOXL2LOXTAAR1MAOB | |
| SCHEMBL8690013 | 0.83 | LOXL2 (0.47) | KIF11DAOLOXL2LOXTAAR1 | |
| SCHEMBL6066285 | 0.82 | DAO (0.50) | KIF11DAOKDM1ATAAR1SLC7A5 | |
| SCHEMBL1690346 | 0.82 | LOXL2 (0.41) | KIF11DAOLOXL2LOXTAAR1 | |
| SCHEMBL11938564 | 0.82 | LOXL2 (0.41) | KIF11DAOLOXL2LOXTAAR1 | |
| SCHEMBL3718586 | 0.81 | KIF11 (0.56) | KIF11TAAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025042797-A1 | TRIM7 INHIBITORS AND USES THEREOF | SHATTUCK LABS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-117534631-B | Phenylthiazole amine PI4KIII beta inhibitor, preparation method, pharmaceutical composition and application thereof | 南京市鸿舜医药科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | TMX1, P2RX1, TCOF1 | KIF11 2252/4885DAO 1700/4885KDM1A 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.